

Optimization of localized colloidal systems for the treatment of periodontal pockets

A Thesis Submitted By

Heba Abdel Moniem Abdel Rahman Gad

Assistant Lecturer at the Department of Pharmaceutics and Industrial Pharmacy
Faculty of Pharmacy, Ain Shams University
Master of Pharmaceutical Sciences, 2007, Ain Shams University

For fulfillment of the requirements for degree of philosophy of
Pharmaceutical Sciences (Drug Technology)

Under the Supervision of

Prof. Dr. Omaila Ahmed Sammour

*Professor and head of department of Pharmaceutics and Industrial
Pharmacy
Faculty of Pharmacy - Ain Shams University*

Prof. Dr. Hadir Fouad EL Dessouky

*Professor of Periodontology, Oral Medicine and Oral Diagnosis
Faculty of Dentistry - Ain Shams University.*

Dr. Amany Osama Kamel

*Associate Professor of Pharmaceutics and Industrial Pharmacy
Faculty of Pharmacy - Ain Shams University*

Department of Pharmaceutics and Industrial Pharmacy
Faculty of Pharmacy
Ain Shams University
Cairo, Egypt
2013

تعظيم أنظمة غروية لعلاج الجيوب الفموية

رسالة مقدمة من

هبة عبد المنعم عبد الرحمن جاد

المدرس المساعد بقسم الصيدلانيات والصيدلة الصناعية - كلية الصيدلة - جامعة عين شمس

ماجستير في العلوم الصيدلانية - 2007 - جامعة عين شمس

وذلك لاستكمال متطلبات الحصول على درجة الدكتوراه في العلوم الصيدلانية
(تخصص تكنولوجيا الأدوية)

تحت اشراف

ا.د. أميمة أحمد سمور

استاذ و رئيس قسم الصيدلانيات والصيدلة الصناعية - كلية الصيدلة - جامعة عين شمس

ا.د. هدير فؤاد الدسوقي

استاذ علاج اللثة و طب الفم والتشخيص - كلية طب اسنان - جامعة عين شمس

د. أماني أسامة كامل

استاذ مساعد الصيدلانيات والصيدلة الصناعية - كلية صيدلة - جامعة عين شمس

Acknowledgement

I am deeply thankful to Allah by the grace of whom the present work was realized.

First of all, I would like to express my deepest gratitude and appreciation to **Prof. Dr. Omaina Ahmed Sammour**, Professor and head of department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University for suggesting the point, her instructive supervision, continuous advice and supportive encouragement.

I would like to express my deep and sincere gratitude and regards to **Prof. Dr. Hadir Fouad EL Dessouky**, Professor of Periodontology, Oral Medicine and Oral diagnosis, Faculty of Dentistry, Ain Shams University for her great help and valuable comments.

I would like to extend a special thanks to **Dr. Amany Osama Kamal**, Associate professor of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University for planning the work, her instructive discussion, unlimited advice and her great effort devoted towards the completion of this thesis.

I would like to thank **Prof. Dr. Mohamed Mabrouk**, Professor and head of department of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University for his valuable advice and offering facilities to complete the microbiological part.

I would like to thank **Prof. Dr. Ahmed Abdel Aziz**, Professor of Periodontology, Oral Medicine and Oral diagnosis, Faculty of Dentistry, Ain Shams University for his help in performing the clinical part.

I would like to thank **Dr. Ola Ezzat**, Lecturer of Periodontology, Oral Medicine and Oral diagnosis, Faculty of Dentistry, Ain Shams University for her great help in performing the clinical part.

I would like to thank **Dr. Nancy Magdy**, Lecturer of Analytical Pharmaceutical Chemistry, Faculty of Pharmacy, Ain Shams University, for her help in constructing the first derivative spectra.

I would like to thank **Pharmacist Ahmed Abu Zied**, Assistant Lecturer of Microbiology and Immunology, Faculty of Pharmacy, Ain Shams University, for his great help in performing the microbiological part.

Grateful thanks are extended to my colleagues and all workers in Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University.

I would like to extend a special acknowledgment to **my husband and my sons (Ahmed & Amr)** for their encouragement, support, and most of all their patience for which I am truly grateful.

A special debt of gratitude is gladly acknowledged to **my father and brother** for their encouragement and finally, words could never express my deep feelings toward my **beloved mother and my twin**, for their sincere help, support and enduring the difficult times during this work.

Contents

Abbreviations List	i
List of Tables	iii
List of Figures	ix
Abstract	xiv
General Introduction	1
Scope of work	19

Chapter I

Preparation and characterization of doxycycline hydrochloride and metronidazole loaded proniosomal gel

Introduction	20
Experimental	27
Methods	
I- Determination of λ_{\max} of doxycycline hydrochloride and metronidazole in phosphate buffer (pH 7.4).....	29
II- Construction of calibration curves of doxycycline hydrochloride and metronidazole.....	29
III- Preparation of doxycycline hydrochloride and metronidazole loaded proniosomes.....	29
A- Selection of an appropriate carrier for the preparation of proniosomes....	29
B- Preparation of proniosomes.....	30
C- Formation of niosomes from proniosomes.....	30
D- Study of the influence of various formulation parameters.....	30
i- Effect of surfactant structure.....	30
ii- Effect of cholesterol content.....	31
iii- Effect of surfactant loading.....	31
iv- Effect of drug structure and amount.....	31
E- Evaluation of the niosomal suspensions.....	31
i- Microscopic examination	31
1- Optical microscopy.....	31
2- Transmission electron microscopy (TEM).....	31
ii- Determination of doxycycline hydrochloride and metronidazole entrapment efficiencies.....	32
iii- Determination of vesicle size, size distribution and zeta potential.....	32
iv- <i>In-vitro</i> release study.....	32
IV- Physicochemical characterization of proniosomes powder.....	33
A- Scanning electron microscopy (SEM).....	33
B- Powder flowability.....	33
C- Differential scanning calorimetry (DSC).....	34
D- Fourier transform infrared (FT-IR) spectroscopy.....	34

V- Stability studies.....	34
VI- Incorporation of proniosomes into poloxamer gel.....	34
A- Preparation of poloxamer gel.....	34
B- <i>In-vitro</i> release study.....	35
VII- Data analysis.....	35
Results and Discussion.....	36
I- Determination of λ_{\max} of doxycycline hydrochloride and metronidazole in phosphate buffer (pH 7.4).....	36
II- Construction of calibration curves of doxycycline hydrochloride and metronidazole applying first order derivative.....	38
III- Proniosomes.....	40
A- Selection of an appropriate carrier for the preparation of proniosomes....	40
B- Formation of niosomes from proniosomes.....	42
i- Microscopic examination.....	42
1- Optical microscopy.....	42
2- Transmission electron microscopy.....	42
ii- Determination of doxycycline hydrochloride and metronidazole entrapment efficiencies.....	44
1- Effect of surfactant structure.....	44
2- Effect of cholesterol content.....	46
3- Effect of surfactant loading.....	50
4- Effect of drug structure and amount.....	51
iii- Vesicle size and zeta potential analysis.....	55
1- Effect of surfactant structure.....	55
2- Effect of cholesterol content.....	56
3- Effect of surfactant loading.....	58
4- Effect of drug amount.....	59
iv- <i>In-vitro</i> release of doxycycline hydrochloride and metronidazole from proniosomes derived niosomes.....	59
1- Effect of surfactant structure.....	59
2- Effect of cholesterol content.....	63
3- Effect of surfactant loading.....	69
4- Effect of drug amount.....	72
IV- Physicochemical characterization of the optimum proniosomes powder.....	78
A- Scanning electron microscopy (SEM).....	78
B- Powder flowability.....	82
C- Differential scanning calorimetry (DSC).....	83
D- Fourier transform infrared (FT-IR) spectroscopy.....	85
V- Stability studies.....	87
VI- Incorporation of proniosomes into poloxamer gel.....	88
Conclusions.....	92

Chapter II

Preparation and characterization of doxycycline hydrochloride and metronidazole loaded solid lipid microparticles gel

Introduction.....	95
Experimental.....	101
Methods	
I- Partitioning nature of metronidazole between different lipids and water.....	103
II- Preparation of doxycycline hydrochloride and metronidazole loaded solid lipid microparticles.....	103
A-Study of the influence of various formulation parameters.....	103
i- Effect of lipid type.....	103
ii- Effect of homogenization speed.....	104
iii- Effect of total drug amount.....	104
iv- Effect of varying doxycycline hydrochloride to metronidazole percent	104
v- Effect of surfactant type and concentration.....	104
vi- Effect of addition of glyceryl monostearate.....	104
B-Evaluation of solid lipid microparticles.....	105
i- Microscopic examination.....	105
1- Optical microscopy	105
2- Transmission electron microscopy (TEM).....	105
ii- Determination of doxycycline hydrochloride and metronidazole entrapment efficiencies.....	105
iii- Determination of particle size and zeta potential.....	105
iv- <i>In-vitro</i> release study.....	105
III- Freeze drying of solid lipid microparticles dispersions.....	107
A- Freeze-drying process	107
B- Evaluation of the freeze dried solid lipid microparticles	107
i- Determination of doxycycline hydrochloride and metronidazole entrapment efficiencies.....	107
ii- Determination of particle size and zeta potential	107
iii- <i>In-vitro</i> release study	107
iv- Scanning electron microscopy (SEM).....	107
v- Differential scanning calorimetry (DSC)	108
vi- Fourier transform infrared (FT-IR) spectroscopy.....	108
IV- Stability studies	108
V- Incorporation of solid lipid microparticles into poloxamer gel	108
A- Preparation of poloxamer gel	108
B- <i>In-vitro</i> release study.....	108
VI- Data analysis.....	109
Results and Discussion	110
I- Partitioning nature of metronidazole between different lipids and water.....	110

II- Evaluation of solid lipid microparticles.....	110
A- Microscopic examination.....	111
1- Optical microscopy	111
2- Transmission electron microscopy.....	111
B- Determination of doxycycline hydrochloride and metronidazole entrapment efficiencies.....	113
i- Effect of lipid type	113
ii- Effect of homogenization speed.....	115
iii- Effect of total drug amount	116
iv- Effect of varying doxycycline hydrochloride to metronidazole percent	116
v- Effect of surfactant type and concentration.....	118
vi- Effect of addition of glyceryl monostearate	123
C- Particle size and zeta potential analysis	124
i- Effect of lipid type	124
ii- Effect of homogenization speed.....	125
iii- Effect of total drug amount	126
iv- Effect of varying doxycycline hydrochloride to metronidazole percent	127
v- Effect of surfactant type and concentration	127
vi- Effect of addition of glyceryl monostearate	131
D- <i>In-vitro</i> release of doxycycline hydrochloride and metronidazole from solid lipid microparticles.....	132
III- Freeze drying of optimized solid lipid microparticles formulae.....	146
A- Evaluation of the freeze dried solid lipid microparticles	146
i- Entrapment efficiencies of doxycycline hydrochloride and metronidazole.....	146
ii- Particle size and zeta potential analysis.....	150
iii- <i>In-vitro</i> release study	151
iv- Scanning electron microscopy (SEM).....	155
v- Differential scanning calorimetry (DSC)	156
vi- Fourier transform infrared (FT-IR) spectroscopy.....	158
IV- Stability studies.....	160
V- Incorporation of solid lipid microparticles into poloxamer gel	162
Conclusions.....	165

Chapter III

Clinical and microbiological evaluation of the selected formulae

Introduction.....	167
Subjects & Methods.....	170
Methods	
I- Preparation of the different formulations.....	171

A- Preparation of doxycycline hydrochloride and metronidazole loaded proniosomal gel.....	171
B- Preparation of doxycycline hydrochloride and metronidazole loaded solid lipid microparticles gel.....	171
C- Preparation of doxycycline hydrochloride and metronidazole loaded poloxamer gel.....	171
II- Histopathological evaluation after application of the selected formulations....	171
III- Clinical study design	172
A- Subjects	172
B- Selection criteria.....	172
C- Patients grouping	173
D- Treatment protocol.....	173
E- Criteria for evaluation	174
i- Microbiological evaluation.....	174
1- Sampling from pockets.....	174
2- Determination of bacterial count.....	175
ii- Clinical evaluation.....	176
1- Plaque index (PI)	176
2- Gingival index (GI)	177
3- Papillary bleeding index (PBI)	177
4- Probing pocket depth (PPD).....	177
5- Clinical attachment level (CAL).....	177
IV- Data analysis	178
Results and Discussion.....	179
I- Histopathological evaluation after application of the selected formulations....	179
II- Clinical study	181
A- Microbiological evaluation.....	181
i- Total anaerobic count.....	181
ii- Total aerobic count.....	190
B- Clinical evaluation.....	199
i- Plaque index (PI)	199
ii- Gingival index (GI)	201
iii- Papillary bleeding index (PBI)	203
iv- Probing pocket depth (PPD).....	205
v- Clinical attachment level (CAL).....	207
Conclusions & Recommendations.....	216
Summary	217
References.....	226
Consent form	254
Arabic summary.....	258

Abbreviations List

BOP	Bleeding on probing
CAL	Clinical attachment level
CFUs	Colony forming units
CH	Cholesterol
DH	Doxycycline hydrochloride
DSC	Differential scanning calorimetry
Ep	Epikuron
Fig.	Figure
FT-IR	Fourier transform infrared
GCF	Gingival crevicular fluid
GI	Gingival index
GMS	Glyceryl monostearate
g	gram(s)
HLB	Hydrophilic lipophilic balance
HPMC	Hydroxypropylmethyl cellulose
h.	Hour
hrs.	Hours
mg	Milligram
MIC	Minimum inhibitory concentration
min	Minute
ml	Milliliter
mM	Millimole
m.p.	Melting point
MT	Metronidazole
mV	Millivolt
Mwt	Molecular weight
My52	Myrj 52
My59	Myrj 59
nm	Nanometer
PBI	Papillary bleeding index
PCL	Poly ϵ -caprolactone
PDI	Polydispersity index
PPD	Probing pocket depth
PI	Plaque index
PLA	Poly lactide
PLGA	PolyLactide co glycolide
P188	Poloxamer 188
P407	Poloxamer 407
rpm	Revolution per minute

SA	Stearic acid
SD	Standard deviation
SE	Standard error
Sec	Second
SEM	Scanning electron microscope
SLMs	Solid lipid microparticles
SLNs	Solid lipid nanoparticles
Sp	Span
SRP	Scaling and root planning
SRP+G	Scaling and root planning + Poloxamer Gel
SRP+P	Scaling and root planning + Proniosomes gel
SRP+S	Scaling and root planning + Solid lipid microparticles gel
T_c	Transition temperatures
TEM	Transmission electron microscope
TP	Tripalmitin
TS	Tristearin
Tw80	Tween 80
μg	Microgram
μm	Micrometer
U.V.	Ultraviolet
λ_{max}	Lambda maximum

List of Tables

Table No.	Page
1 Relationship between doxycycline hydrochloride and metronidazole concentrations and their absorbance at 263nm and 350nm respectively applying U.V. 1 st order derivative.....	38
2 Effect of surfactant type on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into proniosomes derived niosomes (1mM lipid/gram carrier without cholesterol, 20mg of each drug).....	45
3 Effect of cholesterol content on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into proniosomes derived niosomes (1mM lipid/gram carrier, 20mg of each drug).....	48
4 Effect of surfactant loading on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into proniosomes derived niosomes (Sp 60:CH (9:1), 20mg of each drug).....	50
5 Effect of drug amount on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into proniosomes derived niosomes (Sp 60:CH (9:1)).....	54
6 Effect of proniosomes derived niosomes composition on vesicle size and zeta potential.....	57
7 Effect of surfactant loading on vesicle size and zeta potential of proniosomes derived niosomes (Sp 60:CH (9:1)).....	58
8 Effect of surfactant type on the <i>in-vitro</i> release of doxycycline hydrochloride from proniosomes derived niosomes in phosphate buffer pH (7.4).....	61
9 Effect of surfactant type on the <i>in-vitro</i> release of metronidazole from proniosomes derived niosomes in phosphate buffer pH (7.4).....	61
10 Effect of cholesterol content on the <i>in-vitro</i> release of doxycycline hydrochloride from Sp 40 proniosomes derived niosomes in phosphate buffer pH (7.4).....	65
11 Effect of cholesterol content on the <i>in-vitro</i> release of metronidazole from Sp 40 proniosomes derived niosomes in phosphate buffer pH (7.4).....	65
12 Effect of cholesterol content on the <i>in-vitro</i> release of doxycycline hydrochloride from Sp 60 proniosomes derived niosomes in phosphate buffer pH (7.4).....	67
13 Effect of cholesterol content on the <i>in-vitro</i> release of metronidazole from Sp 60 proniosomes derived niosomes in phosphate buffer pH (7.4).....	67

Table No.	Page
14 Effect of surfactant loading on the <i>in-vitro</i> release of doxycycline hydrochloride from proniosomes derived niosomes in phosphate buffer pH (7.4).....	70
15 Effect of surfactant loading on the <i>in-vitro</i> release of metronidazole from proniosomes derived niosomes in phosphate buffer pH (7.4).....	70
16 Effect of drug amount on doxycycline hydrochloride and metronidazole <i>in-vitro</i> release from proniosomes derived niosomes in phosphate buffer pH (7.4).....	72
17 Kinetic data of doxycycline hydrochloride release from proniosomes derived niosomes prepared from different spans and cholesterol ratios in phosphate buffer (pH 7.4).....	75
18 Kinetic data of doxycycline hydrochloride release from proniosomes derived niosomes prepared from different surfactant loadings per gram carrier in phosphate buffer (pH 7.4).....	75
19 Kinetic data of doxycycline hydrochloride release from proniosomes derived niosomes prepared from different drug amounts in phosphate buffer (pH 7.4).....	76
20 Kinetic data of metronidazole release from proniosomes derived niosomes prepared from different spans and cholesterol ratios in phosphate buffer (pH 7.4)...	76
21 Kinetic data of metronidazole release from proniosomes derived niosomes prepared from different surfactant loadings per gram carrier in phosphate buffer (pH 7.4).....	77
22 Kinetic data of metronidazole release from proniosomes derived niosomes prepared from different drug amounts in phosphate buffer (pH 7.4).....	77
23 Angle of repose of proniosomes prepared using different surfactant loadings.....	82
24 Effect of storage temperatures on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into proniosomes (Sp 60:CH, 9:1).....	88
25 <i>In-vitro</i> release of doxycycline hydrochloride and metronidazole from proniosomes in poloxamer gel in comparison to proniosomes derived niosomes in phosphate buffer (7.4).....	89
26 Kinetic data of doxycycline hydrochloride and metronidazole release from proniosomes in poloxamer gel in phosphate buffer (pH 7.4).....	91
27 Partition coefficient of metronidazole in different lipids.....	110

Table No.	Page
28 Effect of lipid type on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into solid lipid microparticles (2.5%w/w poloxamer 188 : Epikuron (1:1) surfactants and 2.5%w/w of each drug at 8000 rpm for 3 minutes)...	114
29 Effect of homogenization speed on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into solid lipid microparticles (5% w/w tripalmitin or tristearin lipid matrix, 2.5%w/w poloxamer 188 : Epikuron (1:1) surfactants and 2.5%w/w of each drug).....	115
30 Effect of total drug amount on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into solid lipid microparticles (5%w/w tripalmitin lipid matrix, 2.5%w/w poloxamer 188 : Epikuron (1:1) surfactants at 4000 rpm for 3 minutes).....	116
31 Effect of varying doxycycline hydrochloride to metronidazole percent on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into solid lipid microparticles (5%w/w tripalmitin lipid matrix, 2.5%w/w poloxamer 188 : Epikuron (1:1) surfactants at 4000 rpm for 3 minutes).....	118
32 Effect of surfactant type and concentration on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into solid lipid microparticles (5%w/w tripalmitin lipid matrix, 25mg DH, 100mg MT at 4000 rpm for 3 minutes).....	121
33 Effect of addition of glyceryl monostearate on the entrapment efficiencies of doxycycline hydrochloride and metronidazole into solid lipid microparticles (2.5%w/w poloxamer 188 : Epikuron (1:1) surfactants, 25mg DH, 100mg MT at 4000 rpm for 3 minutes).....	123
34 Effect of lipid type on the size of and zeta potential of solid lipid microparticles (2.5%w/w poloxamer 188 : Epikuron (1:1) surfactants, 2.5%w/w of each drug at 8000 rpm for 3 minutes).....	125
35 Effect of homogenization speed on the size and zeta potential of solid lipid microparticles (5%w/w tripalmitin or tristearin lipid matrix, 2.5%w/w poloxamer 188 and Epikuron (1:1) surfactants and 2.5%w/w of each drug).....	126

Table No.	Page
36 Effect of total drug amount on the size and zeta potential of solid lipid microparticles (5%w/w tripalmitin lipid matrix and 2.5%w/w poloxamer 188 and Epikuron (1:1) surfactants at 4000 rpm for 3 minutes).....	126
37 Effect of varying doxycycline hydrochloride to metronidazole percent on the size and zeta potential of solid lipid microparticles (5%w/w tripalmitin lipid matrix and 2.5%w/w poloxamer 188 and Epikuron (1:1) surfactants at 4000 rpm for 3 minutes).....	127
38 Effect of surfactant type and concentration on the size and zeta potential of solid lipid microparticles (5%w/w tripalmitin lipid matrix, 25mg DH, 100mg MT at 4000 rpm for 3 minutes).....	130
39 Effect of addition of glyceryl monostearate on the size and zeta potential of solid lipid microparticles (2.5%w/w poloxamer 188 : Epikuron (1:1) surfactants, 25mg DH, 100mg MT at 4000 rpm for 3 minutes).....	132
40 The composition of selected solid lipid microparticles subjected to <i>in-vitro</i> release study	133
41 <i>In-vitro</i> release of doxycycline hydrochloride from solid lipid microparticles stabilized using 2.5%w/w surfactant(s) in phosphate buffer pH (7.4).....	135
42 <i>In-vitro</i> release of metronidazole from solid lipid microparticles stabilized using 2.5%w/w surfactant(s) in phosphate buffer pH (7.4).....	135
43 <i>In-vitro</i> release of doxycycline hydrochloride from solid lipid microparticles stabilized using 5%w/w surfactant(s) in phosphate buffer pH (7.4).....	138
44 <i>In-vitro</i> release of metronidazole from solid lipid microparticles stabilized using 5%w/w surfactant(s) in phosphate buffer pH (7.4).....	138
45 Effect of using different ratios of tripalmitin to glyceryl monostearate on the <i>in-vitro</i> release of doxycycline hydrochloride from solid lipid microparticles stabilized using 2.5%w/w poloxamer and Epikuron (1:1) in phosphate buffer pH (7.4).....	141
46 Effect of using different ratios of tripalmitin to glyceryl monostearate on the <i>in-vitro</i> release of metronidazole from solid lipid microparticles stabilized using 2.5%w/w poloxamer and Epikuron (1:1) in phosphate buffer pH (7.4).....	141